CDNA vs PCVX
CareDx, Inc vs Vaxcyte, Inc. — AI-powered side-by-side comparison
VS
PCVX
Vaxcyte, Inc.
66
Insufficient Data
| Metric | CDNA | PCVX |
|---|
| AI Score |
59
|
66
|
| Price |
$47.20
|
$59.22
|
| P/E Ratio |
21.95×
|
-7.75×
|
| ROE |
-7.0%
|
-28.5%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
70.6%
|
0.0%
|
| Debt / Equity |
0.05×
|
0.04×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
74.3
|
65.6
|
| Beta |
2.419
|
1.21
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for CDNA versus PCVX.
PCVX leads by 7 points.
PCVX scores 66/100 (Insufficient Data) versus CDNA at 59/100 (Buy).
CDNA Committee View
75% agreement
4 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Risk Analyst remains cautious — bollinger bandwidth of 50.3% signals elevated volatility. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
- RSI at 74 is in overbought territory — Technical
- Weekly RSI at 86 -- overbought on the larger timeframe too — Technical
- Bollinger bandwidth of 50.3% signals elevated volatility — Risk
PCVX Committee View
67% agreement
3 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- Price structure (LH_LL) contradicts the uptrend -- mixed signals — Technical